Beam Therapeutics Company Profile: Stock Performance & Earnings

Beam Therapeutics Overview

Founded
2017

Status
Public

Employees
341

Stock Symbol
BEAM

Investments
2

Share Price
$62.81
(As of Monday Closing)

Beam Therapeutics General Information

Description

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

Contact Information

Website

www.beamtx.com

Ownership Status

Publicly Held

Financing Status

Formerly VC-backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Stock Exchange

NAS

Primary Office

26 Landsdowne Street
2nd Floor
Cambridge, MA 02139
United States

+1 (857) 000-0000





Beam Therapeutics Timeline

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beam Therapeutics Stock Performance

(As of Monday Closing)

Stock Price	Previous Close	52 wk Range	Market Cap	Shares	Average Volume	EPS
$62.81	$64.05	$56.34 - $138.52	$4.4B	68.7M	895K	-$5.77

Beam Therapeutics Financials Summary

In Thousands, USD	TTM 31-Dec-2021	FY 2021 31-Dec-2021	FY 2020 31-Dec-2020	FY 2019 31-Dec-2019
EV	4,641,777	4,641,777	4,564,455
Revenue	51,844	51,844	24	18
EBITDA	(363,178)	(363,178)	(190,908)	(77,051)
Net Income	(370,638)	(370,638)	(194,592)	(78,326)
Total Assets	1,474,453	1,474,453	451,677	156,099
Total Debt	147,644	147,644	107,644	31,238

Public Fundamental Data provided by Morningstar, Inc. disclaimer

Beam Therapeutics Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.

Request a free trial

Beam Therapeutics Cap Table

Stock	# of Shares Authorized	Par Value	Dividend Rate (%)	Original Issue Price	Liquidation	Liquidation Pref. Multiple	Conversion Price	% Owned

This information is available in the PitchBook Platform. To explore Beam Therapeutics‘s full profile, request access.

Request a free trial

Beam Therapeutics Comparisons

Description

Primary
Industry

HQ Location

Employees

Total Raised

Post Valuation

Last Financing Details

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technol

Drug Discovery

Cambridge, MA

341 As of 2021

00000

000000000 00000

0000000

luptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pro

0000000000000

Beijing, China

000 As of 0000

00000

0000 0000-00-00

00000000000 00000

0000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida

0000000000000

Brisbane, CA

000 As of 0000

0000

00000000 0000

Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beam Therapeutics Competitors (57)

Company Name	Financing Status	Location	Employees	Total Raised	Last Financing Date/Type	Last Financing Amount
EdiGene	Venture Capital-Backed	Beijing, China	000	00000	00000000000	00000
0000000 0000000000	Formerly VC-backed	Brisbane, CA	000	0000	00000000	0000
000000000 00000000	Venture Capital-Backed	Hayward, CA	00	000.00	00000000000	000.00
0000000 0000000000	Formerly VC-backed	Berkeley, CA	00	00000	00000000	00000
00000 000000000000	Venture Capital-Backed	Cambridge, MA	00	00000	00000000000	00000

You’re viewing 5 of 57 competitors. Get the full list »

Beam Therapeutics Patents

51
Total Documents Applications and Grants
000
Total Patents Families
2
Granted
14
Pending
000
Expiring in next 12 mo

Beam Therapeutics Recent Patent Activity

Publication ID	Patent Title	Status	First Filing Date	Technology (CPC)
AU-2020223306-A1	Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease	Pending	13-Feb-2019	000000000
AU-2020223060-A1	Compositions and methods for treating hemoglobinopathies	Pending	13-Feb-2019	0000000000
AU-2020221355-A1	Compositions and methods for treating glycogen storage disease type 1a	Pending	13-Feb-2019	0000000000
AU-2020223297-A1	Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease	Pending	13-Feb-2019	0000000000
AU-2020223314-A1	Compositions and methods for treating alpha-1 antitrypsin deficiency	Pending	13-Feb-2019	C12N15/102

To view Beam Therapeutics’s complete patent history, request access »

Beam Therapeutics Executive Team (14)

Name	Title	Board Seat	Contact Info
John Evans	Chief Executive Officer & Board Member
Giuseppe Ciaramella Ph.D	Chief Scientific Officer & President
Terry-Ann Burrell	Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Susan O'Connor	Chief Human Resources Officer
Christine Bellon Ph.D	Senior Vice President and Chief Legal Officer

You’re viewing 5 of 14 executive team members. Get the full list »

Beam Therapeutics Board Members (9)

Name	Representing	Role
Carole Ho MD	Self	Board Member
Graham Cooper	Self	Board Member
John Evans	Beam Therapeutics	Chief Executive Officer & Board Member
John Maraganore Ph.D	Self	Board Member
Kathleen Walsh	Self	Board Member